ADVA unveils commercially ready disaggregated cell site gateway solution at TIP ’19
ADVA (FSE: ADV) today announced the commercial readiness of its disaggregated cell site gateway (DCSG) solution at the Telecom Infra Project (TIP) Summit. Powered by ADVA’s Ensemble Activator network operating system (NOS), the integrated white box solution comes with a comprehensive bundle of installation, commissioning and monitoring services for rapid network deployment. The technology is currently on display in a 5G demo at the TIP Summit with ADVA’s software running on Edgecore’s new family of DCSG devices. The showcase highlights how mobile network operators (MNOs) now have an easy and cost-effective route to mass small cell deployment for 5G services. Already successful in a series of trials in global MNO networks, Ensemble Activator is the industry’s only true carrier-grade NOS for bare-metal switches.
“This is a landmark moment for mobile networks. Now that MNOs can leverage our DCSG solution as a simple and complete answer for evolving their infrastructure to 5G, the shackles are off. We’re empowering them to roll out widespread small cell networks in a way that’s simple, affordable and future-proof. Our technology and complete service bundle make the transition easy so that MNOs are free to focus instead on the business opportunities that 5G offers,” said Eli Angel, VP, product line management, Ethernet access, ADVA. “This TIP demo also highlights the value of openness and disaggregation in mobile networks. By enabling software to be separated from hardware, we’re giving operators the freedom to select the ideal technology combination for their needs and harness the latest and greatest innovation.”
The new DCSG solution has been engineered to TIP’s white box gateway specifications. By giving MNOs the power to move away from a closed proprietary system to an open, disaggregated and vendor-neutral infrastructure, it provides the opportunity to massively increase network efficiencies. What’s more, the new DCSG technology enables an open approach, accelerating innovation cycles and reducing CAPEX. As well as providing a NOS, protocol support, dynamic configurability, and manageability, the DCSG solution also delivers IEEE 1588 timing with optional SFP-based GNSS backup. Powered by Ensemble Activator, the DCSG technology is the second commercial offering ADVA has developed for TIP, following its successful rollout of a packet optical solution built around the Voyager optical white box.
“It’s great to see how rapidly this community has produced results. After only 12 months, our initiative has pushed DCSG technology from concept to reality and created a solution ready for deployment in live networks. With ADVA’s Ensemble Activator becoming generally available, operators have a clear roadmap to the next generation of mobile networks,” commented Luis MartinGarcia, co-lead, DCSG project group, TIP. “MNOs can now harness a complete and fully tested DCSG solution that enables them to address today’s key challenges. It opens the door to the deployment of the hundreds of thousands of cell site gateways needed to address the mobile backhaul demands of 5G.”
“What we’re presenting to the industry here at TIP ’19 is a new and innovative method of building and deploying telecom networks. We’re showcasing a way to tackle the most pressing challenges of 4G and emerging 5G mobile networks by enabling open technology choices and delivering the cost-efficiency of disaggregation. ADVA’s Ensemble Activator running on our cell site gateway family of products offers the ultimate route to lower costs and increased service flexibility,” said Matt Roman, VP, marketing and product management, Edgecore. ”The rapid success of this project is due to the close collaboration of our teams. Working together with ADVA, we’ve built an integrated technology which, when coupled with a rich set of supporting services, enables MNOs to utilize a truly cohesive open cell site solution.”
ADVA’s new DCSG solution will be on display at the TIP Summit’s LiveLab from November 13 to 14.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191113005408/en/
Contact information
For ADVA press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For ADVA investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 09:42:00 EET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 09:30:00 EET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 04:06:00 EET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
